Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ .
Bharti ManglaPriya MittalPankaj KumarShamama JavedWaquar AhsanGeeta AggarwalPublished in: Nanomedicine (London, England) (2024)
Aims: This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG) intended for topical application for the treatment of ductal carcinoma in situ . Materials & methods: The optimized process involved a thin-film hydration method to generate ERL-loaded transferosomes (ERL@TFS), which was incorporated into a carbopol gel matrix to generate ERL@TG. The optimized formulation was characterized in vitro followed by cytotoxicity evaluation on MCF-7 breast cancer cell lines and acute toxicity and skin irritation studies was performed in vivo . Results: In a comparative assessment against plain ERL, ERL@TG displayed enhanced efficacy against MCF-7 cell lines, reflected in considerably lower IC 50 values with an enhanced safety profile. Conclusion: Optimized ERL@TG was identified as a promising avenue for addressing ductal carcinoma in situ breast cancer.
Keyphrases
- wound healing
- drug delivery
- cancer therapy
- epidermal growth factor receptor
- advanced non small cell lung cancer
- breast cancer cells
- oxidative stress
- hyaluronic acid
- drug induced
- liver failure
- young adults
- respiratory failure
- tyrosine kinase
- combination therapy
- replacement therapy
- aortic dissection
- mechanical ventilation